Primary Ovarian Insufficiency Global Market Report 2025
상품코드:1760701
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
원발성 난소 부전증 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년까지 10.0%의 연평균 성장률(CAGR)로 17억 3,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 보조생식술의 이용 확대, 가임력 보존 옵션의 채택 확대, 맞춤형 의료에 대한 관심 증가, 호르몬 요법의 인기 상승, 가임력 보존 기술의 이용 확대가 성장을 견인할 것으로 예상됩니다. 이 기간의 주요 동향으로는 진단 기술의 발전, 유전자 검사의 통합, 가임력 보존의 혁신, 비호르몬 요법의 개발, 조기 발견 바이오마커의 발전 등을 꼽을 수 있습니다.
자가 면역 질환의 유병률 증가는 원발성 난소 부전증(POI) 시장의 성장을 촉진할 것으로 예상됩니다. 자가면역질환은 면역체계가 인체의 건강한 세포와 조직을 잘못 공격하여 손상을 입힐 때 발생합니다. 자가면역질환의 증가는 주로 유전적 소인에 기인하며, 면역계 기능 장애에 취약한 특정 유전자를 물려받았기 때문입니다. 원발성 난소 부전증(POI)은 호르몬 불균형과 면역 체계의 조절 장애가 어떻게 상호 작용하여 환자에서 자가 면역 질환의 위험을 증가시키는지 보여줌으로써 자가 면역 질환에 대한 인사이트를 제공할 수 있습니다. 예를 들어, 2024년 11월 독일에 기반을 둔 조직인 Versorgungsatlas.de는 2022년 7,324만 1,305명의 피보험자 중 630만 4,340명이 적어도 한 가지 이상의 자가면역질환을 앓고 있으며, 유병률은 8.61%였다고 보고했습니다. 따라서 자가면역질환의 유병률 증가가 원발성 난소기능부전증 시장의 성장에 기여하고 있습니다.
원발성 난소 부전증 시장의 주요 기업들은 난소 기능을 회복하고 불임 치료 결과를 개선하기 위해 동종 엑솜 요법과 같은 혁신적인 치료법 개발에 주력하고 있습니다. 동종 엑소좀 치료는 기증자 줄기세포 유래 세포외 소포(엑소좀)를 이용하여 POI 환자의 조직 복구를 촉진하고 난소 기능을 회복시키는 재생 신호를 전달합니다. 예를 들어, 2022년 10월 미국 생명공학 기업 Vitti Labs LLC는 미국 식품의약국(FDA)으로부터 원발성 난소 부전증 치료제 EV-Pure의 승인을 받았습니다. 이 치료제는 간엽 간질 세포 유래 엑소좀의 재생, 면역 조절, 항염증 특성을 활용하여 난소 기능과 생식 능력을 회복시킵니다. 이 치료법은 악성화 및 면역거부반응과 같은 세포 기반 치료에 수반되는 위험을 피하면서 조직 복구 및 항상성을 촉진하는 생물학적 활성 분자를 전달하는 기성품 무세포 솔루션을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 원발성 난소 부전증PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
Johns Hopkins Medicine Overview, Products and Services, Strategy and Financial Analysis
Baptist Health Overview, Products and Services, Strategy and Financial Analysis
Ferring Pharmaceuticals A/S Overview, Products and Services, Strategy and Financial Analysis
The Kingsley Natural Health Clinic Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
PreventionGenetics LLC
The Fertility Partnership(TFP) UK
Celmatix Inc.
European Society of Human Reproduction and Embryology(ESHRE)
Endocrine Society
IVIRMA Global
American Society for Reproductive Medicine(ASRM)
TCM Healthcare(UK) Ltd.
Bioscience Institute S.p.A.
Sparsh Diagnostics Pvt. Ltd.
Welling Homeopathy Clinics Pvt. Ltd.
Bristol Menopause Clinic
Indira IVF Hospital Private Limited
Lawley Pharmaceuticals Pty. Ltd.
OvaScience Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
원발성 난소 부전증시장 2029 : 새로운 기회를 제공하는 국가
원발성 난소 부전증시장 2029 : 새로운 기회를 제공하는 부문
원발성 난소 부전증시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Primary ovarian insufficiency (POI) is a condition in which the ovaries stop functioning properly before the age of 40, leading to reduced estrogen production and irregular or absent menstrual periods. This condition can result in infertility and is often linked to hormonal imbalances, even though some ovarian activity may still be present.
The main treatments for primary ovarian insufficiency include hormone replacement therapy (HRT), calcium and vitamin D supplements, in vitro fertilization (IVF), stem cell therapy, and other options. Hormone replacement therapy (HRT) involves supplementing hormones, typically estrogen and progesterone, to alleviate symptoms caused by hormonal imbalances or deficiencies, particularly during menopause. Diagnostic methods for POI include blood tests, ultrasound imaging, and genetic testing. This condition can affect individuals across different age groups, including those under 20, 20 to 30 years old, 30 to 45 years old, and those over 45. The treatments are used by various end users, such as hospitals, clinics, and specialized fertility centers.
The primary ovarian insufficiency market research report is one of a series of new reports from The Business Research Company that provides primary ovarian insufficiency market statistics, including the primary ovarian insufficiency industry's global market size, regional shares, competitors with the primary ovarian insufficiency market share, detailed primary ovarian insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the primary ovarian insufficiency market. This primary ovarian insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The primary ovarian insufficiency market size has grown rapidly in recent years. It will grow from $1.07 billion in 2024 to $1.18 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of autoimmune disorders, rising stress levels, a higher incidence of genetic mutations, a growing number of women delaying childbirth, and a rising prevalence of endocrine disorders.
The primary ovarian insufficiency market size is expected to see rapid growth in the next few years. It will grow to $1.73 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. In the forecast period, growth is expected to be driven by the growing use of assisted reproductive technologies, increased adoption of fertility preservation options, a stronger focus on personalized medicine, rising popularity of hormonal therapies, and a greater use of fertility preservation techniques. Key trends during this period include advancements in diagnostic technologies, the integration of genetic testing, innovations in fertility preservation, the development of non-hormonal therapies, and progress in early detection biomarkers.
The increasing prevalence of autoimmune disorders is expected to drive the growth of the primary ovarian insufficiency (POI) market. Autoimmune disorders occur when the immune system mistakenly attacks and damages the body's own healthy cells and tissues. The rise in autoimmune disorders is primarily attributed to genetic predisposition, where individuals inherit certain genes that make them more vulnerable to immune system malfunctions. Primary ovarian insufficiency (POI) can provide insights into autoimmune disorders by showing how hormonal imbalances and immune system dysregulation interact, leading to a heightened risk of autoimmune diseases in affected individuals. For instance, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, reflecting a prevalence rate of 8.61%. Therefore, the increasing prevalence of autoimmune disorders is contributing to the growth of the primary ovarian insufficiency market.
Leading companies in the primary ovarian insufficiency market are focusing on developing innovative therapies, such as allogenic exosomal therapy, to restore ovarian function and improve fertility outcomes. Allogenic exosomal therapy uses extracellular vesicles, or exosomes, derived from donor stem cells to deliver regenerative signals that promote tissue repair and restore ovarian function in patients with POI. For example, in October 2022, Vitti Labs LLC, a US-based biotechnology company, received approval from the US Food and Drug Administration (FDA) for EV-Pure, a treatment for primary ovarian insufficiency. This therapy leverages the regenerative, immunomodulatory, and anti-inflammatory properties of mesenchymal stromal cell-derived exosomes to restore ovarian function and fertility. It provides an off-the-shelf, cell-free solution that avoids the risks associated with cell-based treatments, such as malignant transformation or immune rejection, while delivering bioactive molecules to promote tissue repair and homeostasis.
In July 2023, EQT Private Capital Asia, a China-based investment company, acquired a 60% stake in Indira IVF Hospital Pvt. Ltd. for $1.1 billion. This acquisition aims to expand Indira IVF's market leadership in India and Asia, enhance its technological capabilities, and scale operations to take advantage of the rapidly growing fertility services market. Indira IVF Hospital Pvt. Ltd. is a fertility clinic based in India that specializes in the diagnosis and treatment of primary ovarian insufficiency (POI), also known as premature ovarian failure (POF).
Major players in the primary ovarian insufficiency market are Mayo Clinic, Johns Hopkins Medicine, Baptist Health, Ferring Pharmaceuticals A/S, The Kingsley Natural Health Clinic, PreventionGenetics LLC, The Fertility Partnership (TFP) UK, Celmatix Inc., European Society of Human Reproduction and Embryology (ESHRE), Endocrine Society, IVIRMA Global, American Society for Reproductive Medicine (ASRM), TCM Healthcare (UK) Ltd., Bioscience Institute S.p.A., Sparsh Diagnostics Pvt. Ltd., Welling Homeopathy Clinics Pvt. Ltd., Bristol Menopause Clinic, Indira IVF Hospital Private Limited, Lawley Pharmaceuticals Pty. Ltd., OvaScience Inc.
North America was the largest region in the primary ovarian insufficiency market in 2024. The regions covered in primary ovarian insufficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the primary ovarian insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary ovarian insufficiency market consists of revenues earned by entities by providing services such as fertility treatments, diagnostic and genetic testing services, osteoporosis management services, and endocrinology consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ovarian insufficiency market also consists of sales of products including genetic testing kits, bone health supplements, psychological and supportive care products, testosterone therapy, and antioxidant supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Ovarian Insufficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on primary ovarian insufficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for primary ovarian insufficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary ovarian insufficiency market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Hormone Replacement Therapy (HRT); Calcium and Vitamin D Supplements; In Vitro Fertilization (IVF); Stem Cell Therapy; Other Types
2) By Diagnosis Method: Blood Tests; Ultrasound Imaging; Genetic Testing
3) By Application: Less Than 20 Years Old; 20 To 30 Years Old; 30 To 45 Years Old; 45 Years Old And Older
4) By End-Users: Hospitals And Clinics; Specialty Fertility Centers
5) By Other Types: Psychological Counseling And Support Therapies; Assisted Reproductive Technologies (other than IVF); Immunomodulatory Therapies; Lifestyle And Dietary Interventions
Companies Mentioned: Mayo Clinic; Johns Hopkins Medicine; Baptist Health; Ferring Pharmaceuticals A/S; The Kingsley Natural Health Clinic
3. Primary Ovarian Insufficiency Market Trends And Strategies
4. Primary Ovarian Insufficiency Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Primary Ovarian Insufficiency Growth Analysis And Strategic Analysis Framework
5.1. Global Primary Ovarian Insufficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Primary Ovarian Insufficiency Market Growth Rate Analysis
5.4. Global Primary Ovarian Insufficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Primary Ovarian Insufficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Primary Ovarian Insufficiency Total Addressable Market (TAM)
6.1. Global Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hormone Replacement Therapy (HRT)
Calcium and Vitamin D Supplements
In Vitro Fertilization (IVF)
Stem Cell Therapy
Other Types
6.2. Global Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Tests
Ultrasound Imaging
Genetic Testing
6.3. Global Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Less Than 20 Years Old
20 To 30 Years Old
30 To 45 Years Old
45 Years Old And Older
6.4. Global Primary Ovarian Insufficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Specialty Fertility Centers
6.5. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of Hormone Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Estrogen Therapy
Estrogen-Progestin Therapy
Transdermal Patches
Vaginal Estrogen Products
Oral Hormone Therapy
6.6. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of Calcium And Vitamin D Supplements, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Calcium Carbonate
Calcium Citrate
Vitamin D2 (Ergocalciferol)
Vitamin D3 (Cholecalciferol)
Combined Calcium + Vitamin D Formulations
6.7. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of In Vitro Fertilization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Conventional In Vitro Fertilization
Intracytoplasmic Sperm Injection (ICSI)
Egg Donation In Vitro Fertilization
Embryo Freezing And Transfer
Preimplantation Genetic Testing (PGT)
6.8. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autologous Stem Cell Therapy
Allogeneic Stem Cell Therapy
Mesenchymal Stem Cell (MSC) Therapy
Ovarian Stem Cell Transplantation
6.9. Global Primary Ovarian Insufficiency Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Psychological Counseling And Support Therapies
Assisted Reproductive Technologies
Immunomodulatory Therapies
Lifestyle And Dietary Interventions
7. Primary Ovarian Insufficiency Market Regional And Country Analysis
7.1. Global Primary Ovarian Insufficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Primary Ovarian Insufficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Primary Ovarian Insufficiency Market
9.1. China Primary Ovarian Insufficiency Market Overview
9.2. China Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Primary Ovarian Insufficiency Market
10.1. India Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Primary Ovarian Insufficiency Market
11.1. Japan Primary Ovarian Insufficiency Market Overview
11.2. Japan Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Primary Ovarian Insufficiency Market
12.1. Australia Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Primary Ovarian Insufficiency Market
13.1. Indonesia Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Primary Ovarian Insufficiency Market
14.1. South Korea Primary Ovarian Insufficiency Market Overview
14.2. South Korea Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Primary Ovarian Insufficiency Market
15.1. Western Europe Primary Ovarian Insufficiency Market Overview
15.2. Western Europe Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Primary Ovarian Insufficiency Market
16.1. UK Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Primary Ovarian Insufficiency Market
17.1. Germany Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Primary Ovarian Insufficiency Market
18.1. France Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Primary Ovarian Insufficiency Market
19.1. Italy Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Primary Ovarian Insufficiency Market
20.1. Spain Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Primary Ovarian Insufficiency Market
21.1. Eastern Europe Primary Ovarian Insufficiency Market Overview
21.2. Eastern Europe Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Primary Ovarian Insufficiency Market
22.1. Russia Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Primary Ovarian Insufficiency Market
23.1. North America Primary Ovarian Insufficiency Market Overview
23.2. North America Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Primary Ovarian Insufficiency Market
24.1. USA Primary Ovarian Insufficiency Market Overview
24.2. USA Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Primary Ovarian Insufficiency Market
26.1. South America Primary Ovarian Insufficiency Market Overview
26.2. South America Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Primary Ovarian Insufficiency Market
27.1. Brazil Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Primary Ovarian Insufficiency Market
28.1. Middle East Primary Ovarian Insufficiency Market Overview
28.2. Middle East Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Primary Ovarian Insufficiency Market
29.1. Africa Primary Ovarian Insufficiency Market Overview
29.2. Africa Primary Ovarian Insufficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Primary Ovarian Insufficiency Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Primary Ovarian Insufficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Primary Ovarian Insufficiency Market Competitive Landscape And Company Profiles
